Colin P Dinney
Overview
Explore the profile of Colin P Dinney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
198
Citations
5092
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mokkapati S, Manyam G, Steinmetz A, Tholomier C, Martini A, Choi W, et al.
Transl Oncol
. 2025 Jan;
52:102269.
PMID: 39808845
Bladder cancer (BLCA) genomic profiling has identified molecular subtypes with distinct clinical characteristics and variable sensitivities to frontline therapy. BLCAs can be categorized into luminal or basal subtypes based on...
2.
Fallara G, Belladelli F, Robesti D, Malavaud B, Tholomier C, Mokkapati S, et al.
Urol Oncol
. 2025 Jan;
43(3):188.e9-188.e17.
PMID: 39788823
Objectives: Survival outcomes of patients with metastatic urothelial carcinoma (mUC) are still suboptimal and strategies to enhance response to immune-oncology (IO) compounds are under scrutiny. In preclinical studies, it has...
3.
Steinmetz A, Jazayeri B, Pierce M, Mokkapati S, McConkey D, Li R, et al.
Expert Opin Biol Ther
. 2025 Jan;
25(2):149-159.
PMID: 39779686
Introduction: Approximately 75% of bladder cancer cases are non-muscle invasive at diagnosis. Drug development for non-muscle invasive bladder cancer (NMIBC) has historically lagged behind that of other malignancies. No treatment...
4.
Steinmetz A, Pierce M, Martini A, Tholomier C, Manyam G, Chen Y, et al.
Front Immunol
. 2024 Nov;
15:1387229.
PMID: 39559365
Introduction: Nadofaragene firadenovec (Ad-IFNα/Syn3) is now approved for BCG-unresponsive bladder cancer (BLCA). IFNα is a pleiotropic cytokine that causes direct tumor cell killing via TRAIL-mediated apoptosis, angiogenesis inhibition, and activation...
5.
Steinmetz A, Mokkapati S, McConkey D, Dinney C
Bladder Cancer
. 2024 Aug;
10(2):105-112.
PMID: 39131870
Background: The intravesical gene therapy nadofaragene firadenovec (rAd-IFNα/Syn3) was FDA approved in 2022 for non-muscle invasive bladder cancer (NMIBC) unresponsive to frontline treatment with BCG, and the first gene therapy...
6.
Kamat A, Lobo N, Lerner S, Li R, Matulay J, Palou J, et al.
Bladder Cancer
. 2024 Jul;
8(2):113-117.
PMID: 38993360
When it comes to the treatment of patients with non-muscle-invasive bladder cancer (NMIBC) with intravesical bacillus Calmette-Guérin (BCG), two questions must be considered: 1) what dose to give, and 2)...
7.
Chang E, Hahn N, Lerner S, Fallah J, Agrawal S, Kamat A, et al.
Bladder Cancer
. 2024 Jul;
9(3):271-286.
PMID: 38993184
Background: Despite recent drug development for non-muscle invasive bladder cancer (NMIBC), few therapies have been approved by the US Food and Drug Administration (FDA), and there remains an unmet clinical...
8.
Contieri R, Tan W, Grajales V, Hensley P, Martini A, Bree K, et al.
BJU Int
. 2024 Feb;
133(6):733-741.
PMID: 38374533
Objective: To evaluate the prognostic value of T1 substaging in patients treated with bacillus Calmette-Guérin (BCG) or immediate radical cystectomy (iRC). Materials And Methods: We performed an institutional review board-approved...
9.
Ho M, Black A, Zargar H, Fairey A, Mertens L, Dinney C, et al.
Can Urol Assoc J
. 2023 Oct;
17(10):301-309.
PMID: 37851909
Introduction: Cisplatin-based neoadjuvant chemotherapy (NAC) is the standard of care for patients with muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy (RC). Cisplatin, however, can induce renal toxicity. Furthermore, RC is...
10.
Contieri R, Hensley P, Tan W, Grajales V, Bree K, Nogueras-Gonzalez G, et al.
Eur Urol Oncol
. 2023 Aug;
6(6):590-596.
PMID: 37558542
Background: European Urology Association (EAU) guidelines recommend immediate radical cystectomy (early RC) for patients with very high-risk (VHR) non-muscle invasive bladder cancer (NMIBC), with bacillus Calmette-Guérin (BCG) recommended only for...